Curevac, Company

Berlin, June 17 German biopharmaceutical company CureVac's mRNA-based vaccine has shown efficacy of just 47 per cent against Coronavirus disease, the lowest reported so far from any Covid-19 vaccine maker.The trial of vaccine candidate CVnCoV, which included nearly 40,000 volunteers from 10 countries, did not meet pre-specified statistical success criteria, according to the preliminary results of a clinical trial reported on Wednesday."The variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge," said Franz-Werner Haas, Chief Executive Officer of CureVac, in a statement.The vaccine maker assessed 134 Covid-19 cases in this interim analysis. Out of these cases, 124 were sequenced to identify the variant causing the infection. The trial will continue with a minimum of 80 additional cases and the final analysis is expected in two to three weeks, the company said."We're going full speed for the final readout. We are still planning to filing for approvala Haas was quoted as saying by the New York Times.The results caught scientists by surprise. The vaccine is made from engineered mRNA, the same technology used by the Pfizer-BioNTech and Moderna vaccines. And CureVac's shots yielded promising results in animal experiments and early clinical trials.According to Haas, the disappointing results were due to the high number of virus variants in the countries where the vaccine was tested latin America and Europe. Out of 124 of the Covid-19 cases that the company's scientists genetically sequenced, only one was caused by the original version of the coronavirus.More than half of the cases (57 per cent) were caused by Variants of Concern. Most of the remaining cases were caused by other less characterised variants such as Lambda or C37, first identified in Peru (21 per cent) and B1621, first identified in Colombia (7 per cent).In this context, the interim results suggest efficacy in younger participants but did not allow to conclude on efficacy in the age group above 60, the company said.The results should serve as a wake-up call for the threat that new variants can pose to the effectiveness of vaccines, Haas was quoted as saying by the NYT. CureVac is searching for new RNA molecules that can work against many variants at once, as well as combining RNA molecules tailored to different variants in a single dose. "It's a new Covid reality, that's for sure," he said.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

CurevacFOLLOW

Curevac, Latest News

New York, Aug 21 Swedish music streaming giant Spotify has announced to spend up to $1 billion between ... ...

Berlin, Aug 17 The second mRNA Covid-19 Vaccine developed by German biopharmaceutical company CureVac and its British partner ... ...

One of the first global companies to break all the critical barriers of taste, price, and shelf-stability at room temperature, GoodDot is perfectly poised for explosive growth with the help of this investment and support from Sixth Sense Venture, Ind ...

TVS Motor Company registered a growth of 10% with sales of 278,855 units in July 2021 as against sales of 252,744 units in the month of July 2020. ...

New Delhi, July 7 The shareholders of Reliance Infrastructure Limited (Reliance Infra), through postal ballot, have approved with ... ...

Prabhuji Online, India's fastest growing technology enabled "Subscription Commerce Company", has raised an undisclosed amount of funds in pre-series A round from Singapore and India based marquee angel investors. ...

Godfrey Phillips India bags the coveted title of Best Companies to Work For 2021. Participating for the third year, Godfrey Phillips India received a ranking of 28th this year. ...

Berlin, June 17 German biopharmaceutical company CureVac's mRNA-based vaccine has shown efficacy of just 47 per cent against ... ...